The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C09 | Agents acting on the renin-angiotensin system | |
| 3 | C09B | ACE inhibitors, combinations | |
| 4 | C09BB | ACE inhibitors and calcium channel blockers | |
| 5 | C09BB02 | Enalapril and lercanidipine |
| Active Ingredient | Description | |
|---|---|---|
| Enalapril and Lercanidipine |
Fixed combination of an ACE-inhibitor, enalapril, and a calcium channel blocker, lercanidipine, two antihypertensive compounds with complementary mechanism of action to control blood pressure in patients with essential hypertension. The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| LERCARIL 10 mg/10 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| LERCARIL 20 mg/10 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| LERCARIL 20 mg/20 mg Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
